Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Aminopeptidase Antibodies In Mesothelioma: New Wine Deserves New Sacks

J. Van Meerbeeck, G. Jansen, E. Giovannetti, G. Peters
Published 2018 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
In this issue of the European Respiratory Journal, Otsuki et al. [1] postulate that antibody targeting of aminopeptidase N (APN)/CD13 by MT95-4 might be a potential therapeutic approach for malignant pleural mesothelioma (MPM). Aminopeptidases have several functions, but their main role is breakdown of small peptides [2]. However, aminopeptidases may also play a role in angiogenesis. Angiogenesis signalling is an important hallmark of solid cancer pathophysiology in general and MPM in particular [3]. Several mechanisms are involved in this process; one of the most important factors is the shedding by the tumour of the ligand vascular endothelial growth factor (VEGF), which then binds to the homologous receptor (VEGFR) on blood vessels. This signal leads to neo-angiogenesis: the sprouting of fragile, distorted and aberrant feeding vessels to the tumour. MPM has amongst the highest expression of VEGF and an increased vascularisation is a poor prognostic factor [4]. Aminopeptidase antibodies are a new class of agents in mesothelioma; their development will require strategic clinical trials. Exploring activity and efficacy according to old paradigms may lead to their disruptive characteristics being disregarded. http://ow.ly/3XLU30jUpqf
This paper references
10.1002/(SICI)1096-9896(199706)182:2<211::AID-PATH834>3.0.CO;2-D
EVALUATION OF TUMOUR ANGIOGENESIS AS A PROGNOSTIC MARKER IN MALIGNANT MESOTHELIOMA
S. Kumar-Singh (1997)
10.1158/0008-5472.CAN-07-6627
CHR-2797: an antiproliferative aminopeptidase inhibitor that leads to amino acid deprivation in human leukemic cells.
D. Krige (2008)
Preclinical investigation of the therapeutic potential of nintedanib in malignant pleural mesothelioma
V Laszlo (2016)
10.1515/cclm.1988.26.12.795
Human Aminopeptidases: A Review of the Literature
G. J. Sanderink (1988)
10.1016/j.lungcan.2017.05.012
Cost-effectiveness analysis of additional bevacizumab to pemetrexed plus cisplatin for malignant pleural mesothelioma based on the MAPS trial.
M. Zhan (2017)
10.1200/JCO.2011.41.5869
Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma.
H. Kindler (2012)
10.1007/s00726-013-1648-0
Positioning of aminopeptidase inhibitors in next generation cancer therapy
Sarina Hitzerd (2013)
10.1093/annonc/mdq173
Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
R. Stahel (2010)
10.1093/annonc/mdq020
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
M. Reck (2010)
10.5306/wjco.v7.i5.352
Role of Akt signaling in resistance to DNA-targeted therapy
A. Avan (2016)
10.2174/1389200013338748
Bestatin as an experimental tool in mammals.
O. A. Scornik (2001)
[Treatment of malignant pleural mesothelioma].
T. Yusa (2007)
10.1183/13993003.01610-2017
Aminopeptidase N/CD13 as a potential therapeutic target in malignant pleural mesothelioma
T. Otsuki (2018)
10.1200/JCO.2017.72.9012
Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial.
F. Grosso (2017)
10.1136/thoraxjnl-2017-211321
British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma
I. Woolhouse (2018)
10.1038/bjc.2013.368
Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma
G. Ceresoli (2013)
10.1093/annonc/mdv249
A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS).
N. Cherny (2015)
10.1200/JCO.2009.27.6295
Phase I/II clinical study of Tosedostat, an inhibitor of aminopeptidases, in patients with acute myeloid leukemia and myelodysplasia.
B. Löwenberg (2010)
10.1111/j.1349-7006.2010.01826.x
Aminopeptidase N (CD13) as a target for cancer chemotherapy
M. Wickström (2011)
10.1038/bjc.2011.400
Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin
E. Giovannetti (2011)
10.1016/j.cell.2011.02.013
Hallmarks of Cancer: The Next Generation
D. Hanahan (2011)
10.1016/j.molmed.2008.06.003
The moonlighting enzyme CD13: old and new functions to target
Paola Mina-Osorio (2008)
10.1182/BLOOD-2006-02-002931
CD13/APN regulates endothelial invasion and filopodia formation.
Nenad Ž. Petrović (2007)
10.1016/S0140-6736(15)01238-6
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial
G. Zalcman (2016)
10.1200/jco.2009.27.15_suppl.535
Outcome prediction by the 70-gene profile in the context of the National Comprehensive Cancer Network (NCCN) guidelines.
F. D. de Snoo (2009)
10.1056/NEJMOA061884
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.
A. Sandler (2006)
10.1200/JCO.2017.76.6394
Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline.
H. Kindler (2018)
10.1183/09031936.00063109
Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma
A. Scherpereel (2009)
10.1093/annonc/mdx499
Role of proton-coupled folate transporter in pemetrexed resistance of mesothelioma: clinical evidence and new pharmacological tools
E. Giovannetti (2017)



Semantic Scholar Logo Some data provided by SemanticScholar